In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
News|Podcasts|June 24, 2026
ACT Brief: Operation TrialBlazer Launched, Protocol Complexity Rising, and Data Infrastructure for AI
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine HHS coordinated effort to restore US clinical research leadership, two decades of rising protocol complexity, and data architecture frameworks for AI sustainability.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- HHS
launched Operation TrialBlazer, a coordinated FDA and NIH effort to reduce US trial friction and counter China's growing clinical research share. The initiative includes an Expedited IND pilot with rolling institutional submissions, a Phase I Contact Center, updated CMC guidance for early-stage trials, and single-trial approval flexibility for late-stage programs. - New
research published on ACT examined protocol complexity across 190,000 trials from 2004–2025, finding endpoints doubled from median 3 to 7, driven almost entirely by secondary endpoints. Failure rates rose modestly from 10.2% to 13.2%, with Phase II consistently the highest-failure phase and oncology now representing 34% of clinical trial activity. - In a Pharmaceutical Technology
article , Partha Anbil and Vineet Kumar evaluated three clinical data management architectures—warehouses, lakes, and lakehouses—using FAIR principles plus the 5 V's framework to guide selection for bias-controlled, interoperable AI development.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Trending on Applied Clinical Trials Online
1
Syneos Health, Optum Partner on Adaptive Clinical Development Model
2
Where AI Governance in Clinical Development Falls Short
3
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
4
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
5